MX2019006326A - Derivados de tirosina y composiciones que los comprenden. - Google Patents

Derivados de tirosina y composiciones que los comprenden.

Info

Publication number
MX2019006326A
MX2019006326A MX2019006326A MX2019006326A MX2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A
Authority
MX
Mexico
Prior art keywords
compositions
tyrosine hydroxylase
hydroxylase inhibitor
tyrosine derivatives
subject
Prior art date
Application number
MX2019006326A
Other languages
English (en)
Inventor
Hoffman Steven
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of MX2019006326A publication Critical patent/MX2019006326A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Son proporcionadas composiciones y equipos que comprenden un inhibidor de la tirosina hidroxilasa y un agente anticáncer que está unido químicamente a, o asociado físicamente con el inhibidor de la tirosina hidroxilasa. También se proporcionan métodos para reducir la proliferación celular en un sujeto que comprende administrar un sujeto que necesite de los mismo una composición que comprende un inhibidor de la tirosina hidroxilasa y un agente anticáncer que es unido químicamente a, o asociado físicamente con, el inhibidor de la tirosina hidroxilasa.
MX2019006326A 2016-11-30 2017-11-30 Derivados de tirosina y composiciones que los comprenden. MX2019006326A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
MX2019006326A true MX2019006326A (es) 2019-07-12

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006326A MX2019006326A (es) 2016-11-30 2017-11-30 Derivados de tirosina y composiciones que los comprenden.

Country Status (12)

Country Link
EP (1) EP3548086A1 (es)
JP (2) JP2019536783A (es)
KR (1) KR20190089191A (es)
CN (1) CN110062633A (es)
AU (1) AU2017368135A1 (es)
BR (1) BR112019011033A2 (es)
CA (1) CA3045110A1 (es)
EA (1) EA201991305A1 (es)
IL (1) IL266840A (es)
MX (1) MX2019006326A (es)
PH (1) PH12019501186A1 (es)
WO (1) WO2018102506A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
MX2021013901A (es) 2019-05-14 2022-04-12 Tyme Inc Composiciones y métodos para el tratamiento del cáncer.
AU2021207666A1 (en) * 2020-01-17 2022-09-01 Tyme, Inc. Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP3075247B1 (en) * 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
JP2009534381A (ja) * 2006-04-19 2009-09-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 細胞画像化および治療のための組成物および方法
ES2569215T3 (es) * 2007-09-10 2016-05-09 Boston Biomedical, Inc. Un nuevo grupo de inhibidores de la ruta de Stat3 e inhibidores de la ruta de las células madre del cáncer
CA2862689C (en) * 2012-01-17 2020-03-10 Tyme, Inc. .alpha.-methyl-dl-tyrosine, compositions, kits, combinations and use thereof for the treatment of cancer or for reducing cell proliferation
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
AU2017368135A1 (en) 2019-06-13
IL266840A (en) 2019-07-31
PH12019501186A1 (en) 2020-02-10
CA3045110A1 (en) 2018-06-07
BR112019011033A2 (pt) 2019-10-15
KR20190089191A (ko) 2019-07-30
EP3548086A1 (en) 2019-10-09
WO2018102506A1 (en) 2018-06-07
EA201991305A1 (ru) 2019-10-31
CN110062633A (zh) 2019-07-26
JP2022153587A (ja) 2022-10-12
JP2019536783A (ja) 2019-12-19

Similar Documents

Publication Publication Date Title
CR20190478A (es) Inhibidores de pd-1/pd-l1
PH12019501186A1 (en) Tyrosine derivatives and composition comprising them
CR20210013A (es) Inhibidores de pd-1/pd-l1
MY195110A (en) Antibodies to PD-1 and uses Thereof
CR20200347A (es) Inhibidores pd-1/pd-l1
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
MX2017013613A (es) Neoepitodos de cancer.
MY199019A (en) Pd-1 antibodies
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MX2019007276A (es) Composiciones y métodos para mejora o aumento de la producción de ifn tipo i.
AU2018341571A8 (en) Therapeutic methods relating to HSP90 inhibitors
TWD173671S (zh) 通訊耳機之部分
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
CR20110553A (es) Terapia complementaria contra el cáncer
EP4389142A3 (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
WO2017132746A8 (en) Ubiquitin variants and uses thereof as 53bp1 inhibitors
WO2018009507A8 (en) COMBINATION OF A TIM -4 ANTAGONIST AND METHODS OF USE
MX2017008414A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
MX2017011521A (es) Composiciones topicas que comprenden un corticosteroide.
WO2015181624A3 (en) Nucleoside derivatives for the treatment of cancer
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2021008839A (es) Composiciones aglomerantes y metodos para fabricacion y uso de las mismas.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.